Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sufotidine (AH 25352X) 是一种具有高度选择性的竞争性 H2 受体拮抗剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,750 | 现货 | ||
5 mg | ¥ 4,360 | 现货 | ||
10 mg | ¥ 6,220 | 现货 | ||
25 mg | ¥ 9,390 | 现货 | ||
50 mg | ¥ 12,600 | 现货 |
产品描述 | Sufotidine (AH 25352X) is a highly selective competitive H2 receptor antagonist. |
体外活性 | The acid inhibitory effect of sufotidine, a potent, long-lasting, competitive H2-receptor antagonist, was studied in 12 healthy males in a double-blind, randomized, three-way cross-over study of the effect of placebo, sufotidine 600 mg nocte and sufotidine 600 mg b.d. given over 15 days. On days 1 and 15 of dosing with each regimen, each subject's 24-hour ambulatory intragastric acidity was measured by radiotelemetry, and 24-hour plasma gastrin profiles were derived from hourly venous blood samples. Acid suppression was calculated as the decrease in the area under the curve of hydrogen ion activity vs time from that observed on placebo, and 24-h plasma gastrin was calculated as the area under the curve of plasma gastrin concentration vs time. 24h intragastric acidity during the fifteenth day of dosing with sufotidine 600 mg nocte and sufotidine 600 mg b.d. did not differ significantly, but on the first and fifteenth day of dosing nocturnal acidity was decreased to a greater extent by sufotidine 600 mg nocte than sufotidine 600 mg b.d. (P less than 0.005). After 15 days, the acid suppression afforded by sufotidine 600 mg b.d. was significantly attenuated (P less than 0.0005); this was associated with a rise in 24-h plasma gastrin (P less than 0.001). Thus, tolerance to the acid-inhibitory effect of H2-receptor antagonists exists and is of rapid onset.[1] |
别名 | AH 25352X, AH25352X, AH-25352X |
分子量 | 421.56 |
分子式 | C20H31N5O3S |
CAS No. | 80343-63-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (130.47 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3721 mL | 11.8607 mL | 23.7214 mL | 59.3035 mL |
5 mM | 0.4744 mL | 2.3721 mL | 4.7443 mL | 11.8607 mL | |
10 mM | 0.2372 mL | 1.1861 mL | 2.3721 mL | 5.9304 mL | |
20 mM | 0.1186 mL | 0.593 mL | 1.1861 mL | 2.9652 mL | |
50 mM | 0.0474 mL | 0.2372 mL | 0.4744 mL | 1.1861 mL | |
100 mM | 0.0237 mL | 0.1186 mL | 0.2372 mL | 0.593 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Sufotidine 80343-63-1 GPCR/G Protein Immunology/Inflammation Neuroscience Histamine Receptor AH 25352X AH25352X AH-25352X Inhibitor inhibitor inhibit